AngelMD

OraQ AI is a clinical decision support system headquartered in Alberta, Canada, founded in 2021. The company focuses on empowering patients to improve their wellness practices through a holistic approach. Utilizing artificial intelligence and machine learning, OraQ AI's platform enhances the engagement, diagnosis, and treatment methods employed by dental professionals. By providing advanced assessments and detailed risk profiling, the system enables doctors to verify and validate treatment recommendations, ultimately aiming to redefine patient care in the dental field.

Raydiant Oximetry, Inc. is a medical device company established in 2015 and headquartered in Mountain View, California. The company specializes in the development of a low-cost, non-invasive device that monitors fetal oxygen levels during labor, with the aim of improving health outcomes for mothers and their babies. By providing real-time data on fetal oxygenation, Raydiant Oximetry's technology seeks to enhance patient care, reduce the occurrence of unnecessary cesarean sections, and lower healthcare costs associated with childbirth. The company's innovations are designed to address potential birth injuries and minimize over-intervention in the delivery process, ultimately striving to improve the overall experience and safety of childbirth.

Neumentum, Inc. is a pharmaceutical company focused on the development and commercialization of non-opioid analgesic and neurology products. Founded in 2017 and headquartered in Palo Alto, California, Neumentum aims to provide safe and effective alternatives for pain management that mitigate the risks associated with opioid use, such as misuse and addiction. The company is advancing multiple non-opioid drug candidates, including two phase 3-ready injectable products specifically designed for acute postsurgical pain. Through its innovative platform, Neumentum is committed to addressing unmet medical needs in both hospital and retail markets, offering viable treatment options for patients experiencing acute and chronic pain.

Access Vascular, Inc. is a medical technology company based in Bedford, Massachusetts, founded in 2015. The company specializes in developing innovative venous access devices that utilize advanced hydrogel materials to significantly reduce thrombosis accumulation, a common complication in intravenous therapy. Their product line includes peripherally inserted central catheters, hemodialysis devices, implantable ports, and drug delivery systems. By addressing critical issues such as occlusions and infections, Access Vascular aims to enhance clinical outcomes, lower healthcare costs, and improve patient experiences. The company's HydroPICC catheter exemplifies their commitment to advancing venous access technology, as it offers superior performance over existing solutions, thereby increasing catheter dwell time and minimizing associated complications.

Raydiant Oximetry, Inc. is a medical device company established in 2015 and headquartered in Mountain View, California. The company specializes in the development of a low-cost, non-invasive device that monitors fetal oxygen levels during labor, with the aim of improving health outcomes for mothers and their babies. By providing real-time data on fetal oxygenation, Raydiant Oximetry's technology seeks to enhance patient care, reduce the occurrence of unnecessary cesarean sections, and lower healthcare costs associated with childbirth. The company's innovations are designed to address potential birth injuries and minimize over-intervention in the delivery process, ultimately striving to improve the overall experience and safety of childbirth.

Iterion Therapeutics, Inc. is a clinical-stage biotechnology company based in Houston, Texas, focused on developing innovative therapeutics for cancer treatment. Established in 2010, the company specializes in targeted cancer therapies, with its lead product, Tegavivint, serving as a potent and selective inhibitor of the Wnt/b-catenin signaling pathway. This pathway is known to play a critical role in various cancer-related processes, including cell proliferation and immune evasion. Tegavivint has demonstrated pre-clinical efficacy in several cancer models, such as desmoid tumors, acute myeloid leukemia, osteosarcoma, and various solid tumors. Iterion Therapeutics is actively enrolling patients in a Phase I clinical study of Tegavivint for desmoid tumors at multiple clinical centers across the United States and Canada.

LifeSprout is developing the next generation of synthetic soft tissue substitutes for aesthetic and reconstructive medicine. They offer revolutionary products for aesthetic and regenerative medicine. They have created a platform that looks and behaves like the body’s own tissues. The company is turning this into a suite of products for millions of patients each year with soft tissue losses from aging, cancer, and metabolic disease.

Sensulin, LLC is a biotechnology company based in Oklahoma City, Oklahoma, focused on developing innovative drug delivery solutions through its proprietary Agglomerated Vesicle Technology. Founded in 2011, Sensulin specializes in creating glucose-responsive insulin that aims to replicate the natural functioning of a healthy human pancreas, targeting both type I and type II diabetes. This advanced insulin formulation is designed to eliminate the need for separate basal and prandial insulin, potentially simplifying diabetes management for patients. By reducing the frequency of glucose monitoring and daily injections, Sensulin’s technology offers a promising improvement in the standard of care for individuals living with diabetes, enhancing their quality of life.

Fibralign Corporation specializes in developing advanced biomedical devices using its proprietary Nanoweave® scaffolding technology. Its flagship product, BioBridge® Collagen Matrix, is designed to mimic human tissue structure, influencing cell behavior and orientating collagen fibers to facilitate regenerative repair. Currently, Fibralign is conducting clinical studies to evaluate BioBridge's use in treating and preventing secondary lymphedema, while also advancing research for new applications in ischemia treatment and stem cell/gene therapy delivery devices.

Access Vascular, Inc. is a medical technology company based in Bedford, Massachusetts, founded in 2015. The company specializes in developing innovative venous access devices that utilize advanced hydrogel materials to significantly reduce thrombosis accumulation, a common complication in intravenous therapy. Their product line includes peripherally inserted central catheters, hemodialysis devices, implantable ports, and drug delivery systems. By addressing critical issues such as occlusions and infections, Access Vascular aims to enhance clinical outcomes, lower healthcare costs, and improve patient experiences. The company's HydroPICC catheter exemplifies their commitment to advancing venous access technology, as it offers superior performance over existing solutions, thereby increasing catheter dwell time and minimizing associated complications.

Otomagnetics, Inc. is a biotechnology company based in Rockville, Maryland, that specializes in the development of a proprietary magnetic injection delivery system. This innovative technology enables non-invasive drug delivery to challenging anatomical sites, including the inner and middle ear, as well as the eye and skin. Founded in 2012 as a spin-out from the University of Maryland College Park, Otomagnetics addresses significant medical challenges, such as the impermeability of the blood-labyrinth barrier, which complicates treatment for inner ear diseases. Preclinical studies have demonstrated the efficacy of their system in delivering therapeutic agents to the inner ear and middle ear, showing promise for treating conditions like tinnitus, noise-induced hearing loss, and otitis media. Although Otomagnetics' products are currently experimental and not yet approved for human use, the technology represents a potential breakthrough in non-invasive treatment options in otolaryngology and pediatric medicine.

Qool Therapeutics, Inc. is focused on developing non-invasive temperature management therapies aimed at inducing therapeutic hypothermia. Incorporated in 2005 and headquartered in Menlo Park, California, the company offers innovative solutions designed to preserve cells, improve patient quality of life, and extend lifespan. Its specialized devices provide an effective system for tissue preservation by influencing various cell functions, which helps slow inflammation, limit cell damage, and reduce oxygen requirements for cells. This technology enables medical professionals to offer a safe and straightforward option for patients requiring temperature management.

Noninvasix, Inc., established in 2007, is a medical technology company based in Galveston, Texas. It develops non-invasive precision oximetry systems designed to measure oxygen sufficiency within organs and veins without the need for invasive catheters. The company's primary focus is on monitoring brain oxygenation in preterm babies within newborn intensive care units (NICUs). Noninvasix has raised over $6.8 million in funding, including a seed round in late 2021, and has been supported by grants from the NIH and DOD totaling $6 million. The company's technology has been clinically validated and is protected by a robust IP portfolio comprising 9 U.S. and 8 global patents. Noninvasix has participated in prestigious accelerator programs such as Philips Healthworks and TMCx, and its innovations have earned multiple awards.

KPI Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, specializing in the development of therapies for unmet medical needs in the fields of autoimmunity and chronic pain. Founded in 2013, the company is actively working on several therapeutic candidates, including dalazatide, KPI-150, and KPI-190, aimed at treating systemic autoimmune diseases such as lupus, as well as CSP conopeptide for chronic pain management. KPI Therapeutics collaborates with various partners, including Kineta, Inc., Chimera Biotec, and the University of Washington School of Medicine, to enhance drug development and improve access to innovative medicines. The company is committed to accelerating the transition of promising drug candidates through critical stages of development, ultimately addressing significant patient needs in healthcare.

Kineta, Inc. is a clinical stage biotechnology company based in Seattle, Washington, focused on the development of immunology-based therapeutics for oncology, neuroscience, and virology. The company is advancing a range of innovative therapies, including KCP-506, a non-opioid antagonist for chronic pain, and LHF-535, an oral antiviral targeting Lassa and other arenaviruses by inhibiting viral entry and replication. Kineta is also engaged in developing next-generation immunotherapies, exemplified by KVA12.1, a VISTA blocking immunotherapy designed to reprogram the immune system to combat cancer. With strategic partnerships with notable organizations like Pfizer and Genentech, Kineta aims to leverage its expertise in antiviral therapies and immune modulation to address significant medical challenges. Formerly known as Lecura, Inc., the company was founded in 2007.